Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Common Equity (2020 - 2025)

Historic Common Equity for PROCEPT BioRobotics (PRCT) over the last 6 years, with Q3 2025 value amounting to $380.3 million.

  • PROCEPT BioRobotics' Common Equity rose 5764.83% to $380.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $380.3 million, marking a year-over-year increase of 5764.83%. This contributed to the annual value of $402.2 million for FY2024, which is 4326.52% up from last year.
  • PROCEPT BioRobotics' Common Equity amounted to $380.3 million in Q3 2025, which was up 5764.83% from $385.8 million recorded in Q2 2025.
  • PROCEPT BioRobotics' Common Equity's 5-year high stood at $402.2 million during Q4 2024, with a 5-year trough of -$206.3 million in Q2 2021.
  • Moreover, its 5-year median value for Common Equity was $252.8 million (2022), whereas its average is $225.5 million.
  • In the last 5 years, PROCEPT BioRobotics' Common Equity surged by 26820.66% in 2021 and then tumbled by 3482.03% in 2023.
  • Over the past 5 years, PROCEPT BioRobotics' Common Equity (Quarter) stood at $267.1 million in 2021, then dropped by 26.22% to $197.1 million in 2022, then soared by 42.46% to $280.8 million in 2023, then surged by 43.27% to $402.2 million in 2024, then fell by 5.46% to $380.3 million in 2025.
  • Its Common Equity was $380.3 million in Q3 2025, compared to $385.8 million in Q2 2025 and $389.2 million in Q1 2025.